Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

As discussed previously, I anticipate FreeStyle Libre will continue to drive the overall growth in the medical device segment. Due to the strong performance during the quarter, Abbott raised the ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as Abbott's popular FreeStyle Libre. The company's ...

(Reuters) -Abbott Laboratories slightly ... monitoring products and other medical devices. Sales of continuous glucose ...

Oct 16 (Reuters) - Abbott Laboratories (ABT.N), opens new tab slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand ...

“As a nonprofit organization, Tidepool is dedicated to providing better access to devices and data through interoperable solutions that give all people living with diabetes greater autonomy. We are ...

after beating Wall Street estimates for quarterly earnings on strong demand for its glucose-monitoring products and other medical devices. Sales of continuous glucose monitors such as Abbott’s ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio ... is dedicated to providing better access to devices and data through interoperable solutions ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

The device is similar to Abbott’s FreeStyle Libre, which people with diabetes have been using for years to track their glucose levels. Each disc remains on the arm for 14 days before it must be ...